Ido Dor, CEO of Lavie Bio, will participate in a panel on Ag-Biologicals; in addition, Eran Kosover, CEO of AgPlenus will host a round table on collaborations in the field
Rehovot, Israel – March 14, 2019 – Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that Evogene will be participating in the World Agritech Innovation Summit to take place in San Francisco in March 19-20, 2019.
- Ido Dor, CEO of Lavie Bio (formerly Evogene’s Ag-Biologicals division), will participate in the panel “Are Biologicals the Future of Crop Protection, Sustainability & Food Quality?” scheduled to take place on Wednesday, March 20, 2019, at 2pm.
- Eran Kosover, CEO of AgPlenus (formerly Evogene’s Ag-Chemicals division), will host the round table on “Collaborations after Consolidation: What opportunities exist for small companies?” scheduled to take place on Tuesday March 19, 2019, at 5-6 pm.
All participants will be available to participate in one-on-one meetings.
About Evogene Ltd.:
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for major life science markets through the use of a unique computational predictive biology (CPB) platform incorporating deep scientific understandings and cutting-edge computational technologies. Today, this platform is utilized by the Company and its subsidiaries to discover and develop innovative products in the following areas: ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions and human microbiome-based therapeutics. Each subsidiary or division establishes its product pipeline and go-to-market, as demonstrated in its collaborations with world-leading companies such as BASF, Corteva, Bayer and ICL. For more information, please visit www.evogene.com
Forward Looking Statements
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene’s control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact:
Nir Zalik
IR/PR Manager
E: IR@evogene.com
T: (+972)-8-931-1963
US Investor Relations
Vivian Cervantes
PCG Advisory
E: vivian@pcgadvisory.com
T: 646-863-6274